ARDC Research Link Australia Research Link Australia   BETA Research
Link
Australia
  • ARDC Newsletter Subscribe
  • Contact Us
  • Home
  • About
  • Feedback
  • Explore Collaborations
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation

Need help searching? View our Search Guide.

Advanced Search

Current Selection
Research Topic : type i interferon
Australian State/Territory : VIC
Clear All
Filter by Field of Research
Cellular Immunology (4)
Endocrinology (3)
Autoimmunity (2)
Cardiology (incl. Cardiovascular Diseases) (2)
Central Nervous System (2)
Basic pharmacology (1)
Cell Metabolism (1)
Cellular Nervous System (1)
Clinical chemistry (incl. diagnostics) (1)
Clinical sciences not elsewhere classified (1)
Emergency medicine (1)
Epidemiology (1)
Health Promotion (1)
Immunology not elsewhere classified (1)
Innate Immunity (1)
Medical Biotechnology (1)
Ophthalmology and optometry not elsewhere classified (1)
Public Health and Health Services (1)
Signal Transduction (1)
Filter by Socio-Economic Objective
Search did not return any results.
Filter by Funding Provider
National Health and Medical Research Council (29)
Filter by Status
Closed (29)
Filter by Scheme
NHMRC Project Grants (10)
Project Grants (10)
Program Grants (3)
Programs (2)
Centres of Research Excellence (1)
NHMRC Strategic Awards (1)
Research Fellowships (1)
Targeted Calls (1)
Filter by Country
Australia (28)
Colombia (1)
Filter by Australian State/Territory
VIC (28)
WA (6)
NT (3)
QLD (3)
ACT (2)
NSW (1)
SA (1)
  • Researchers (0)
  • Funded Activities (29)
  • Organisations (0)
  • Funded Activity

    Understanding Neuroinflammation In Alzheimer's Disease

    Funder
    National Health and Medical Research Council
    Funding Amount
    $1,043,216.00
    Summary
    This project opens a new line of enquiry into the cellular signalling mechanisms involved in the progression of AD and establishes whether targeting the involvement of type-1 IFN signalling influences the evolution of AD. New and novel approaches are clearly required to treat AD. Importantly, we believe that neuroinflammation is common to all causes of dementia and targeting the neuroinflammatory pathways has much wider implications than targeting the primary causative pathway.
    More information
    Funded Activity

    Controlling Neuroinflammation In Alzheimers Disease

    Funder
    National Health and Medical Research Council
    Funding Amount
    $639,577.00
    Summary
    Alzheimer’s disease (AD) is the most common neurodegenerative disorder worldwide, with 269,000 Australians currently diagnosed with AD and is expected to soar to about 981,000 by 2050. AD accounts for greater than 60% of all cases of dementia. This grant investigates the role that neuroinflammation plays in the progression and exacerbation of AD and will identify new therapeutic strategies to combat this insidious disease.
    More information
    Funded Activity

    Targeting Cytokine Signalling In Systemic Lupus Erythematosus

    Funder
    National Health and Medical Research Council
    Funding Amount
    $917,626.00
    Summary
    Systemic lupus erythematosus is a disease where the immune system attacks normally healthy tissues. The spontaneous overproduction of signalling molecules called interferons in lupus plays an important role in the severity of the disease. We have found that two proteins, named Bcl6 and PLZF, are important in controlling the interferon response in lupus patients. We propose that identifying how these proteins act to control interferon will aid in developing new treatments for lupus.
    More information
    Funded Activity

    Determinant Spreading And The Role Of The MHC Class II Region In Systemic And Organ-specific Autoimmunity

    Funder
    National Health and Medical Research Council
    Funding Amount
    $140,570.00
    Summary
    Autoimmune diseases are among the most important group of disorders affecting the adult population. In these diseases the immune system damages organs and tissues producing widespread pathology (systemic autoimmunity such as Lupus erythematosus) or localised disease (organ-specific autoimmunity such as insulin dependent diabetes). We understand very little about how and why the immune system attacks the body's own tissues. This study examines how antibodies and T lymphocytes are formed against c .... Autoimmune diseases are among the most important group of disorders affecting the adult population. In these diseases the immune system damages organs and tissues producing widespread pathology (systemic autoimmunity such as Lupus erythematosus) or localised disease (organ-specific autoimmunity such as insulin dependent diabetes). We understand very little about how and why the immune system attacks the body's own tissues. This study examines how antibodies and T lymphocytes are formed against components located inside cells of the body. The study involves genetically modifying mice by introducing key human genes which influence the development of autoimmunity. In this way the role of these human genes can be examined experimentally without having to work exclusively on patients. We also hope that these mice might be important in creating new models of celiac disease and insulin dependent diabetes. The proposed experiments should tell us how these genes contribute to the development of autoimmune disease. This understanding could be relevant devising treatments and interventions to prevent autoimmune diseases.
    Read more Read less
    More information
    Funded Activity

    The Unique Nature Of Gamma Delta T Cell Recognition Resolved Through Interaction With H2-Q10

    Funder
    National Health and Medical Research Council
    Funding Amount
    $699,031.00
    Summary
    The liver is important for both digestion and immunity. Given these opposing functions, the liver must exert control points that prevent the immune system from recognising food products. We have now identified a new molecular target that controls the development of immune cells in the liver.
    More information
    Funded Activity

    Controlling Neuroinflammation In Alzheimer's Disease

    Funder
    National Health and Medical Research Council
    Summary
    Alzheimer’s disease (AD) is the most common neurodegenerative disorder worldwide, with 269,000 Australians currently diagnosed with AD and is expected to soar to about 981,000 by 2050. AD accounts for greater than 60% of all cases of dementia. This grant investigates the role that neuroinflammation plays in the progression and exacerbation of AD and will identify new therapeutic strategies to combat this insidious disease.
    More information
    Funded Activity

    Antigen Presentation, Recognition And The Immune Response

    Funder
    National Health and Medical Research Council
    Funding Amount
    $14,927,045.00
    Summary
    This program focuses on understanding the development of immunity during infection or inflammatory diseases using a broad array of techniques to dissect the function of various immune cell types and to explore the relationship between structure and function of important cell surface molecules. These studies will improve our ability to design new generation vaccines for combating infectious diseases, controlling cancer, or limiting autoimmune or inflammatory diseases.
    More information
    Funded Activity

    Prevention And Cure Of Type 1 Diabetes

    Funder
    National Health and Medical Research Council
    Funding Amount
    $5,289,733.00
    Summary
    The team has been at the forefront of research on type 1 diabetes for over a decade. This form of diabetes is a major chronic disease from childhood, as well as accounting for at least 10% of adult-onset diabetes. It occurs when the body�s immune system attacks and destroys the beta cells in the pancreas that make insulin, the hormone that controls the level of glucose in the blood. The team was one of the first in the world, and is the only one in Australia, to develop screening programs to tes .... The team has been at the forefront of research on type 1 diabetes for over a decade. This form of diabetes is a major chronic disease from childhood, as well as accounting for at least 10% of adult-onset diabetes. It occurs when the body�s immune system attacks and destroys the beta cells in the pancreas that make insulin, the hormone that controls the level of glucose in the blood. The team was one of the first in the world, and is the only one in Australia, to develop screening programs to test and identify people at risk for type 1 diabetes. They showed that the underlying disease could start years before symptoms occurred and discovered genes that determine the rate at which the underlying disease progresses. They have also found evidence that the disease may be triggered by gut viruses called rotaviruses in genetically-susceptible individuals. They showed that type 1 diabetes could be prevented in a mouse model by getting the immune system to make a protective response to insulin, and then went on to apply this in at-risk humans in a controlled trial of intranasal insulin, the first of its kind. They have used genetic techniques not only to pinpoint the mechanisms responsible for killing the beta cells but also to modify the beta cells to make them resistant to attack by these mechanisms. The multidisciplinary approach of the team will be directed to further understanding the genetic and environmental factors underlying type 1 diabetes and the immune mechanisms, particularly involving special white blood cells called T cells, that kill beta cells. A molecular target of the immune attack, the parent of insulin called proinsulin, will be used, paradoxically, as a tool to regulate the immune system and avert the attack. This will be achieved by giving proinsulin via the mucosa of the naso-respiratory tract or via the bone marrow-derived stem cells, initiallyin the mouse model as a test of feasibility for human application. In parallel with these approaches to prevention, specially constructed viruses will be used to transfer several new genes into beta cells to improve their resistance to immune attack, so that they can be transplanted into people with established diabetes without the need for potentially toxic drugs that suppress the immune system overall. The integrated research of the team is helping to provide a sound, rational base for the eventual prevention and cure of type 1 diabetes.
    Read more Read less
    More information
    Funded Activity

    A Novel Lipid Sensitive Kinase And Its Role In Obesity-induced Inflammation And Insulin Resistance.

    Funder
    National Health and Medical Research Council
    Funding Amount
    $560,045.00
    Summary
    It is now apparent that obesity leads to chronic low grade inflammation which results in insulin resistance or pre-diabetes. The mechanisms that link obesity-induced inflammation to insulin resistance are not well understood, but involve lipid oversupply. We have preliminary data identifying that a protein, not known to previously play a role in metabolic diseases, is a critical mediator of lipid-induced inflammation. We will investigate the clinical potential of blocking this protein.
    More information
    Funded Activity

    Research Fellowship - Grant ID:637303

    Funder
    National Health and Medical Research Council
    Funding Amount
    $792,786.00
    Summary
    I am an immunologist investigating how to manipulate immune responses for vaccines and for transplantation in type 1 diabetes.
    More information

    Showing 1-10 of 29 Funded Activites

    • 1
    • 2
    • 3
    Advanced Search

    Advanced search on the Researcher index.

    Advanced search on the Funded Activity index.

    Advanced search on the Organisation index.

    National Collaborative Research Infrastructure Strategy

    The Australian Research Data Commons is enabled by NCRIS.

    ARDC CONNECT NEWSLETTER

    Subscribe to the ARDC Connect Newsletter to keep up-to-date with the latest digital research news, events, resources, career opportunities and more.

    Subscribe

    Quick Links

    • Home
    • About Research Link Australia
    • Product Roadmap
    • Documentation
    • Disclaimer
    • Contact ARDC

    We acknowledge and celebrate the First Australians on whose traditional lands we live and work, and we pay our respects to Elders past, present and emerging.

    Copyright © ARDC. ACN 633 798 857 Terms and Conditions Privacy Policy Accessibility Statement
    Top
    Quick Feedback